Atrial Fibrillation (AFIB) in the ICU: Incidence, Risk Factors, and Outcomes: The International AFIB-ICU Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

OBJECTIVES: To assess the incidence, risk factors, and outcomes of atrial fibrillation (AF) in the ICU and to describe current practice in the management of AF. DESIGN: Multicenter, prospective, inception cohort study. SETTING: Forty-four ICUs in 12 countries in four geographical regions. SUBJECTS: Adult, acutely admitted ICU patients without a history of persistent/permanent AF or recent cardiac surgery were enrolled; inception periods were from October 2020 to June 2021. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We included 1,423 ICU patients and analyzed 1,415 (99.4%), among whom 221 patients had 539 episodes of AF. Most (59%) episodes were diagnosed with continuous electrocardiogram monitoring. The incidence of AF was 15.6% (95% CI, 13.8-17.6), of which newly developed AF was 13.3% (11.5-15.1). A history of arterial hypertension, paroxysmal AF, sepsis, or high disease severity at ICU admission was associated with AF. Used interventions to manage AF were fluid bolus 19% (95% CI 16-23), magnesium 16% (13-20), potassium 15% (12-19), amiodarone 51% (47-55), beta-1 selective blockers 34% (30-38), calcium channel blockers 4% (2-6), digoxin 16% (12-19), and direct current cardioversion in 4% (2-6). Patients with AF had more ischemic, thromboembolic (13.6% vs 7.9%), and severe bleeding events (5.9% vs 2.1%), and higher mortality (41.2% vs 25.2%) than those without AF. The adjusted cause-specific hazard ratio for 90-day mortality by AF was 1.38 (95% CI, 0.95-1.99). CONCLUSIONS: In ICU patients, AF occurred in one of six and was associated with different conditions. AF was associated with worse outcomes while not statistically significantly associated with 90-day mortality in the adjusted analyses. We observed variations in the diagnostic and management strategies for AF.

OriginalsprogEngelsk
TidsskriftCritical Care Medicine
Vol/bind51
Udgave nummer9
Sider (fra-til)1124-1137
Antal sider14
ISSN0090-3493
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The Department of Intensive Care, Rigshospitalet, has received funds for other research projects from the Novo Nordisk Foundation, Sygeforsikringen “danmark,” Pfizer, and Fresenius Kabi, and does contract research for AM-Pharma. The Department of Intensive Care, Copenhagen University Hospital—North Zealand, has received funds for other research projects from the Novo Nordisk Foundation, Sygeforsikringen “danmark,” and other foundations and does contract research for AM-Pharma and Inotrem. Dr. Bestle has received consultancy fee from AM-Pharma. Dr. Wetterslev received funding from The Research Council of Rigshospitalet, The Ehrenreich’s Foundation, and The Danish Society of Anesthesiology and Intensive Care Medicine; he received support for article research from The Research Council of Rigshospitalet, Copenhagen, Denmark. Drs. Granholm’s and Bestle’s institutions received funding from Sygeforsikringen. Dr. Granholm’s institution received funding from The Ehrenreich’s Foundation, the Novo Nordisk Foundation, Pfizer, Fresenius Kabi, and AM-Pharma. Drs. Shen, Gao, and Yang disclosed work for hire. Dr. Bestle received funding from AM-Pharma. Dr. Haranath received funding from Medvarsity. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Funding Information:
Supported, in part, by The Research Council of Rigshospitalet, The Danish Society of Anesthesiology and Intensive Care Medicine, and The Ehrenreich’s foundation. None of the funders had any influence on the study design, conduct, or reporting.

Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.

ID: 365923600